• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

Canada's Biovail to buy Valeant

Mississauga, Ontario - Biovail, Canada’s largest pharmaceutical firm, plans to purchase Valeant Pharmaceuticals, based in Aliso Viejo, Calif., for about $3.3 billion, according to in-Pharmatechnologist.com.

Mississauga, Ontario - Biovail, Canada’s largest pharmaceutical firm, plans to purchase Valeant Pharmaceuticals, based in Aliso Viejo, Calif., for about $3.3 billion, according to in-Pharmatechnologist.com.

The transaction, which awaits shareholder approval, will result in a new combined entity, Valeant Pharmaceuticals International, to be based in Mississauga.

Market analysts say the merger would create a company with estimated revenues of $900 million a year.

Related Videos
E. James Song is featured in this video series.
E. James Song is featured in this video series.
1 KOL is featured in this series.
2 KOLs are featured in this series.
E. James Song is featured in this video series.
E. James Song is featured in this video series.
Benjamin Lockshin, MD, FAAD, is featured in this series.
© 2024 MJH Life Sciences

All rights reserved.